Teva Pharmaceuticals presented new data from the SOLARIS trial showing no PDSS events with olanzapine LAI (TEV-‘749) and shorter hospital stays with UZEDY compared to Invega Sustenna. Olanzapine LAI demonstrated long-term safety and effectiveness, with no PDSS events reported through Week 56. UZEDY was associated with a 2.89-day shorter hospital stay and was favored by healthcare professionals for ease of administration and dosing characteristics. Overall, UZEDY was preferred by 45% of HCPs compared to 38% for Invega Sustenna. The studies were presented at the 2025 Psych Congress Annual Meeting in San Diego. In the SOLARIS trial, olanzapine LAI showed no PDSS events and a consistent systemic safety profile. UZEDY was found to lead to shorter hospital stays and was preferred by HCPs for its dosing and ease of use. Teva is dedicated to developing medications for individuals with complex mental health conditions. The attributes of UZEDY rated most positively included effectiveness, no loading dose, and tolerability. UZEDY was favored due to its lack of a loading dose and subcutaneous administration. Plasma concentrations were reported as better by NP/PAs and physicians compared to RNs. Important safety information and data on schizophrenia were presented at the 2025 Psych Congress Annual Meeting. UZEDY was approved in the U.S. in 2023 for adults with schizophrenia. Invega Sustenna® is a product of Janssen Pharmaceuticals, Inc. Teva will discuss the data in an investor call on September 22, 2025. In the SOLARIS trial, no post-injection delirium/sedation syndrome events were observed with olanzapine LAI, with a consistent safety profile. New data shows UZEDY (risperidone) led to shorter hospital stays and was preferred over Invega Sustenna. Schizophrenia onset is typically in late teens to early 30s, with episodes of remission and relapse. 80% of patients experience multiple relapses in the first five years. UZEDY is indicated for treating schizophrenia in adults but is contraindicated in elderly patients with dementia-related psychosis. Important safety information includes warnings on increased mortality, cerebrovascular events, neuroleptic malignant syndrome, tardive dyskinesia, metabolic changes, hyperprolactinemia, orthostatic hypotension, syncope, falls, and leukopenia. In the SOLARIS trial, no cases of post-injection delirium were observed with olanzapine LAI, and its long-term safety profile was consistent with other formulations. New data shows that UZEDY was associated with shorter hospital stays and preferred by healthcare providers due to dosing ease. Teva is dedicated to developing medicines for those with mental health conditions. UZEDY may cause sedation, cognitive impairment, seizures, dysphagia, and priapism. Common reactions include somnolence, dizziness, and nausea. Drug interactions and precautions are important to consider. Teva is a leading biopharmaceutical company committed to patient health and innovation. In the SOLARIS trial, olanzapine LAI (TEV-749) showed no PDSS events and a consistent safety profile. New data comparing UZEDY (risperidone) and Invega Sustenna (paliperidone palmitate) found UZEDY led to shorter hospital stays and was preferred by HCPs. Teva is dedicated to developing innovative medicines for mental health conditions, including olanzapine LAI and UZEDY. Important risks include competition, regulatory matters, and financial risks. Forward-looking statements caution against undue reliance on predictions. References include data on file and prescribing information for UZEDY. Overall, Teva aims to provide effective treatments for individuals with complex mental health conditions.
Read more at – No instances of post-injection delirium/sedation syndrome observed in SOLARIS trial for olanzapine LAI (TEV-‘749). Teva Pharmaceuticals (www.globenewswire.com)
– New data shows UZEDY (risperidone) associated with shorter hospital stays compared to Invega Sustenna (paliperidone palmitate). Teva Pharmaceuticals (www.globenewswire.com): New Long-term Safety Data from the Completed Phase 3
